Additional information DISCLOSURE/CONFLICT OF INTEREST Michael Berk declares that over the past three years, he has received compensation from Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Norvatis, Mayne Pharma and Servier
It documents how Willow separates platform control from clinician authority and where variability enters the process
Subcutaneous (s.c.) semaglutide at 1 mg once weekly (OW) is safe in T2D patients with chronic kidney disease (CKD)
39 Dungan et al analyzed data from PIONEER trials and found out that the proportion of patients achieving clinically relevant reductions in both HbA1c and body mass were significantly greater in the group treated with orally administered semaglutide versus comparators (liraglutide, empagliflozin, sitagliptin)
2020;105(12):dgaa638
It works by mimicking a natural hormone (GLP-1) that regulates appetite and blood sugar